We retrospectively reviewed the medical records of patients with metastatic clear cell renal cell carcinoma who received molecular targeted therapy between 2005 and 2011.
Cancer-specific survival was analyzed using the Kaplan-Meier method. Predictors of cancer-specific survival were analyzed using the Cox regression hazards model. A total of 89 patients, consisting of 50 first line patients and 39 patients receiving prior cytokine were included in the analysis. The two-year cancer-specific survival rate of the firstlinegroup was 60.2% and that of theprior cytokinethe rapy group was 62.1%.
In univariateanalysis, Karnofsky performance status (KPS)＜80%, time from diagnosis to treatment less than one year, bone metastasis and C-reactive protein (CRP)＞1.3 mg/dl in were statistically significant prognostic factors (p＜0.05). In multivariate analysis, time from diagnosis to treatment less than one year (HR 2.46, 95%CI 1.11-5.82, p＝0.025) and CRP (HR 4.92, 95%CI 2.23-11.3, p＜0.001) were independent prognostic factors.
Time from diagnosis to treatment less than one year and CRP were independent prognostic factors in patients who received molecular targeted therapy.
Hinyokika Kiyo. 2015 Apr;61(4):135-9.
[Article in Japanese]
Inoue R1, Kitamura H1, Shindo T1, Yanase M2, Takahashi A2, Miyao N2, Ito N2, Hotta H2, Hirose T2, Taguchi K2, Matsukawa M2, Uehara T2, Kunishima Y2, Hotta H2, Masumori N1.
1 The Department of Urology, Sapporo Medical University School of Medicine.
2 Sapporo Medical University Urologic Oncology Consortium.